ALISO VIEJO, Calif.,
Sept. 9 /PRNewswire-FirstCall/ --
Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and
molecular testing services resource for pathologists, oncologists
and the biopharmaceutical industry, today announced that the
Company's presentation time at the Baird 2010 Health Care
Conference has changed to 9:00 am EDT
on Tuesday, September 14, 2010. The
change was made at the request of the Baird Health Care Conference.
The conference will be held September
14-15 at the St. Regis Hotel.
A live webcast of the presentation will be available via a link
provided at http://www.clarientinc.com/investor. An archived replay
of the presentation will also be available for a period of 90 days
from the date of the presentation at
http://www.clarientinc.com/investor.
About Clarient
Clarient combines innovative diagnostic technologies with
world-class pathology expertise to assess and characterize cancer.
Clarient's mission is to become the leader in cancer diagnostics by
dedicating itself to collaborative relationships with the
healthcare community to translate cancer discovery and research
into better patient care. Clarient's principal customers include
pathologists, oncologists, hospitals, and biopharmaceutical
companies. The rise of individualized medicine as the new direction
in oncology has created the need for a centralized resource
providing leading diagnostic technologies, such as flow cytometry
and molecular testing. Clarient is that resource, having created a
state-of-the-art commercial cancer laboratory providing the most
advanced oncology testing and diagnostic services for pathologists
and oncologists. Clarient also provides a complete complement of
commercial services to biopharmaceutical companies and other
research organizations, including diagnostic testing services,
development of companion diagnostics, and clinical trial support.
Clarient also develops and markets new, proprietary "companion"
diagnostic markers for therapeutics in breast, prostate, lung,
ovarian, and colon cancers, and leukemia/lymphoma. Clarient's
customers are connected to its Internet-based portal, PATHSiTE®,
which delivers high resolution images and critical interpretive
reports based on its diagnostic testing. www.clarientinc.com
|
Contact:
|
|
|
Matt Clawson
Allen & Caron,
Inc.
(949) 474-4300
matt@allencaron.com
|
|
|
SOURCE Clarient, Inc.
Copyright t. 9 PR Newswire